Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News


A year of change for Kent Surrey Sussex AHSN

A year of change for Kent Surrey Sussex AHSN
News

KSS AHSN is delighted to publish its 2021/22 Annual Review, in which we look at the developments and innovations that we have been supporting, in what has been another year of significant change.

Adjusting to living with Covid, understanding the role of innovation in Integrated Care Systems on the delivery of healthcare, and our own personnel and organisational changes, have all had an impact on our work this year.

Des Holden, confirmed as Chief Executive Officer in February 2022 after a period as interim CEO, says, ‘What stands out for me is the way we have contributed to the specific needs of our ICSs, and the population we serve, particularly around Covid vaccination for those who were not in the first tranche and were more difficult to accommodate.’

In addition to Covid-related projects, other highlights include:

  • Supporting the formation of a new partnership to deliver equitable care to people with Huntingdon’s Disease.
  • Becoming a founding partner of Surrey Heartlands Health Tech Accelerator, supporting 52 innovators within the first year.
  • Rolling out objective testing for ADHD, using the QbTest system, to six NHS Trusts, on 13 sites, allowing 1,400 tests to be completed for young people.
  • Supporting the spread of Fractional Exhaled Nitric Oxide (FeNO) Testing for asthma, across Kent, Surrey and Sussex, with 54 devices, across 22 sites, benefitting almost 4,000 patients.

We have supported 104 innovators with signposting, guidance and market insights; reached 64 innovators with value proposition, market research and other funding or business support (more than double our target); and offered 45 innovators real-world evaluation, health economics and/or spread activity support (against a target of 10).

As the KSS AHSN comes to the end of its current five year licence, and prepares for the next, Des Holden is excited for the future. ‘We’re going to be looking more at the learning that has come from Covid, particularly around the demand and capacity mismatch that the NHS is facing. There is a range of challenges from safety to access and emergency and elective care, for mental as well as physical health, and we’ll be looking at how we can deliver on that.’

You can read more highlights from the year and plans for the future in Des Holden’s blog.

Related news

Elekta Unity combines magnetic resonance imaging (MRI) with a medical linear accelerator (linac) to improve precision radiotherapy for cancer, potentially reducing treatment burden for patients while improving outcomes.

Case StudyNews

12 Mar 2025

More

Health Innovation Kent Surrey Sussex (KSS) has appointed Chris Hill as Chief Commercial Officer, joining the executive management group to support the organisation through a period of exciting growth.

News

20 Feb 2025

More

MUTU®, the evidence-based digital postnatal recovery platform, has secured its first NHS contract. The programme will be implemented in Medway...

News

19 Feb 2025

More

Elekta Unity combines magnetic resonance imaging (MRI) with a medical linear accelerator (linac) to improve precision radiotherapy for cancer, potentially reducing treatment burden for patients while improving outcomes.

Case StudyNews

12 Mar 2025

More

Health Innovation Kent Surrey Sussex (KSS) has appointed Chris Hill as Chief Commercial Officer, joining the executive management group to support the organisation through a period of exciting growth.

News

20 Feb 2025

More

MUTU®, the evidence-based digital postnatal recovery platform, has secured its first NHS contract. The programme will be implemented in Medway...

News

19 Feb 2025

More